Condition (MeSH)
Familial Primary Pulmonary Hypertension
ClinicalTrials.gov lists 99 trials for Familial Primary Pulmonary Hypertension or a narrower condition beneath it. Bayer has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
99 of the 99 trials are tagged with Familial Primary Pulmonary Hypertension itself; the rest are tagged with a narrower condition beneath it.
When did Familial Primary Pulmonary Hypertension trials start? (27)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 9
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 1 |
| 2024 | 7 |
| 2023 | 8 |
| 2022 | 2 |
| 2021 | 6 |
| 2020 | 2 |
| 2019 | 8 |
| 2018 | 9 |
| 2017 | 4 |
Showing 10 of 27 earlier years.
No forecast is made for this condition: it averages 4.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 35 months from start to primary completion across 10 trials still running at the 2026-10-09 snapshot; registered median of 24 months across 57 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Familial Primary Pulmonary Hypertension trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 9 |
| Phase 1/2 | 1 |
| Phase 2 | 18 |
| Phase 3 | 11 |
| Phase 4 | 6 |
| Not applicable | 24 |
| Observational | 30 |
How many Familial Primary Pulmonary Hypertension trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 13 |
| Enrolling by invitation | 3 |
| Active, not recruiting | 2 |
| Completed | 46 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Familial Primary Pulmonary Hypertension trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Bayer | 4 |
| Liquidia Technologies, Inc. | 3 |
| United Therapeutics | 3 |
| Complexa, Inc. | 2 |
| National Center for Research Resources (NCRR) | 2 |
Showing 5 of 7 sponsors.
Which drugs are being tested for Familial Primary Pulmonary Hypertension? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| ILOPROST | 4 |
| CXA-10 | 2 |
| Ralinepag | 2 |
| BQ123 | 2 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| LIQ861 Inhaled Treprostinil | 2 |
| Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine | 1 |
| BQ-123, MitoQ, BH4 | 1 |
| Supplemental oxygen therapy | 1 |
| NaCl 0.9% NS | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Familial Primary Pulmonary Hypertension trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 6 | 4 |
| Dyspnoea | 5 | 3 |
| Intravenous Medication Line Malfunction/Infection | 4 | 1 |
| Right ventricular failure | 4 | 1 |
| Pericardial effusion | 3 | 3 |
Showing 5 of 10 adverse events.
Which publications cover Familial Primary Pulmonary Hypertension? (149)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Interdependence of hypoxia and β-adrenergic receptor signaling in pulmonary arterial hypertension. | American journal of physiology. Lung cellular and molecular physiology | 2019 | Yes |
| Risk assessment in pulmonary arterial hypertension. | The European respiratory journal | 2018 | Yes |
| Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular-Pulmonary Arterial Coupling. | Lung | 2018 | Yes |
| Effect of calcium channel blockers evaluated by cardiopulmonary exercise testing in idiopathic pulmonary arterial hypertension responding to acute pulmonary vasoreactivity testing. | Pulmonary pharmacology & therapeutics | 2017 | Yes |
| Six-minute walking distance and decrease in oxygen saturation during the six-minute walk test in pediatric pulmonary arterial hypertension. | International journal of cardiology | 2016 | Yes |
Showing 5 of 149 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.